# Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

> **NCT04544319** · PHASE1 · UNKNOWN · sponsor: **LG Chem** · enrollment: 44 (estimated)

## Conditions studied

- T2DM

## Interventions

- **DRUG:** Zemiglo 50mg and Forxiga 10mg
- **DRUG:** Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg

## Key facts

- **NCT ID:** NCT04544319
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10
- **Primary completion:** 2021-03
- **Final completion:** 2021-07
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2020-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04544319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04544319, "Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04544319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*